Heranova Lifesciences, a Boston-based women’s health startup, launches with $13.5 million in seed funding, focusing on reproductive health solutions, including diagnostic testing and therapies for conditions like endometriosis and bacterial vaginosis. The funding will drive the launch of non-invasive endometriosis tests and therapeutic programs. This move aligns with the growing trend of investments in women’s health tech, demonstrated by notable funding rounds in companies like Maven Clinic, Diana Health, Kindbody, and Iron Health.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets and materials.
“We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients,” stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome.
Under the terms of the asset purchase agreement, Immunome would pay Atreca a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. Completion of the transaction is subject to customary conditions including Atreca obtaining a required stockholder vote.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Bio Space
